Semaglutide Oral Research Tablets

These tablets present semaglutide, the acylated 31-residue GLP-1 receptor agonist analogue, in a solid oral research format instead of a lyophilized vial. The peptide itself is unchanged: same CAS number, same molecular formula, same Aib substitution at position 2 and the same gamma-Glu-(AEEA)2-C18 diacid chain conjugated at Lys26. What differs is everything around it. Peptides of this size are ordinarily destroyed by gastric acid and pepsin and absorb poorly across intestinal epithelium, so an oral presentation depends on a co-formulated permeation enhancer of the SNAC type (salcaprozate sodium) that transiently raises local pH and assists paracellular and transcellular passage.

Neighbouring listings mark the boundaries of what this format is for. The lyophilized semaglutide vial supplies the same molecule where the investigator sets concentration and route, while orforglipron is a non-peptide GLP-1 receptor agonist studied orally with no enhancer at all. The tablet sits between them, and the questions it supports are formulation ones: dissolution profiling, the local concentration and residence of the permeation enhancer at the mucosal surface, and the documented variability of absorption for enhancer-dependent oral peptides. Strengths are 3 mg and 7 mg with thirty tablets per bottle, stored sealed at room temperature with the desiccant retained, since moisture ingress bears on the tablet's disintegration behaviour and on the enhancer as much as on the peptide.

The arithmetic on an oral format is unit arithmetic rather than dilution arithmetic. Use the milligram to microgram converter to line a per-unit figure up against a method written in different units.